Nanobiotix sets date for Q4 and 2025 results update

Nanobiotix S.A. filed a report stating it will release its fourth quarter and full year 2025 financial and operational update on March 31, 2026, after the close of the U.S. market.

Rhea-AI Filing Summary

Nanobiotix S.A. filed a report stating it will release its fourth quarter and full year 2025 financial and operational update on March 31, 2026, after the close of the U.S. market. The company will then host a conference call and webcast on April 1, 2026, at 8:00 a.m. EDT / 2:00 p.m. CEST, where senior management will review results and discuss recent business activities before taking questions. Connection details and a replay will be available in the investors section of the company’s website.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nanobiotix (NBTX) report its Q4 and full-year 2025 results?

Nanobiotix will report its Q4 and full-year 2025 financial and operational results on March 31, 2026, after the close of the U.S. market, according to the company’s announcement.

When is the Nanobiotix (NBTX) Q4 and FY 2025 earnings conference call?

The conference call and webcast are scheduled for April 1, 2026, at 8:00 a.m. EDT / 2:00 p.m. CEST, with management reviewing results and providing a business update.

How can investors access the Nanobiotix (NBTX) Q4 and 2025 results webcast?

Investors can access the webcast via links provided in the announcement and in the investors section of www.nanobiotix.com. A replay will be available shortly after the call’s conclusion.

Who will speak on the Nanobiotix (NBTX) Q4 and FY 2025 conference call?

Chief executive officer Laurent Levy and chief financial and business officer Bart van Rhijn will review year-end results and provide a business update before taking participant questions.

Can investors submit questions in advance for the Nanobiotix (NBTX) earnings call?

Yes. Participants are invited to email questions in advance to investors@nanobiotix.com, allowing management to address key investor topics during the conference call.

Where is Nanobiotix (NBTX) headquartered and listed?

Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris and the Nasdaq Global Select Market, reflecting its presence in European and U.S. capital markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 04:15 PM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On March 26, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated March 26, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: March 26, 2026		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

EXHIBIT 99.1

NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST

PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31^st, 2026, after the close of the U.S. market.

This release will be followed by a conference call and webcast on Wednesday, April 1^st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial and business officer, will briefly review the Company’s year-end results and provide an update on business activities for the fourth quarter and full year of 2025 before taking questions from participants.

Details of the call are as follows:

Webcast link: click here
Conference call link: click here

Details of the call are also available in the investors section of the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes prior the event start. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.

Participants are invited to email their questions in advance to investors@nanobiotix.com.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachment

• 2026-03-26 -- NBTX -- 4Q & FY25 STD -- FINAL (https://ml.globenewswire.com/Resource/Download/f70b8332-ec41-44e8-94e9-a3aa3fb38374)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.4 KB